Avadel Pharmaceuticals plc ADR buy stratec
Zusammenfassung
Diese Einschätzung wurde am 05.11.21 mit einem Endkurs von 8,70 € beendet. Aufwärts ging es für die BUY Einschätzung von stratec mit einer Rendite von 23,40 %. stratec hat 50% Zuversicht bei dieser EinschätzungAvadel Pharmaceuticals: A Brief Overview
Avadel Pharmaceuticals (Symbol: FLML, WKN A2DJR8) is a specialty pharmaceutical company publicly traded on the stock exchange, which focuses on the development, manufacturing, and commercialization of innovative pharmaceutical products. By utilizing their proprietary drug delivery technology platform, Avadel aims to improve the performance and patient experience of existing drugs, primarily within the areas of central nervous system (CNS) disorders and sleep medicine. Headquartered in Dublin, Ireland, this company combines both research and development expertise along with strong commercial capabilities to bring unique solutions for patients in need. One of their prominent products, FT218, is an investigational once-nightly sodium oxybate formulation for the treatment of narcolepsy - an example of their dedication to revolutionizing sleep medicine.
Rendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Avadel Pharmaceuticals plc ADR | - | - | - | - |
| iShares Core DAX® | 0,00 % | -2,06 % | 13,11 % | 16,68 % |
| iShares Nasdaq 100 | 0,63 % | -2,88 % | 37,74 % | 43,44 % |
| iShares Nikkei 225® | 1,57 % | -5,89 % | 19,59 % | 4,62 % |
| iShares S&P 500 | 0,33 % | -2,28 % | 27,74 % | 41,05 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Avadel Pharmaceuticals plc ADR diskutieren
In der Diskussion Trading Avadel Pharmaceuticals plc ADR